LBA50 Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: updated results from PROFILE 1014.
Authors
Mok, TKim, D
Wu, YL
Nakagawa, K
Mekhail, T
Felip, E
Cappuzzo, F
Paolini, J
Usari, T
Wilner, K
Blackhall, Fiona H
Solomon, B
Affiliation
Department Of Clinical Oncology, The Chinese University of Hong Kong, 000 - Hong Kong/CNIssue Date
2017